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o.com (B.R. ChallAbstract Obesity can be considered as a chronic illness of epidemic proportion and its incidents have
increased exponentially in recent years. The use of anti-obesity drugs such as sibutramine is somewhat
helpful. There is a need to quantify such drugs in biological samples, which is generally quite difﬁcult. In this
report, we developed and validated a simple, sensitive and speciﬁc liquid chromatography–tandem mass
spectrometry (LC–MS/MS) method for the quantiﬁcation of sibutramine (SB) and its two metabolites
N-des methyl sibutramine (DSB) and N-di desmethyl sibutramine (DDSB) in human plasma. Zorbax SB-
C18 (4.6 mm 75 mm, 3.5 mm, 80 A˚) analytical column and 5 mM ammonium formate:acetonitrile (10:90,
v/v) mobile phase were used for chromatographic separation of SB, DSB and DDSB. Multiple reaction
monitoring (MRM) in the positive mode was used to detect SB, DSB and DDSB at m/z 280.3/124.9, 266.3/
125.3 and 252.2/124.9, respectively. Liquid–liquid extraction was used for the extraction of analytes and
internal standard from human plasma. This method was validated over a linear concentration range of
10.0–10,000.0 pg/mL for SB, DSB and DDSB with correlation coefﬁcients (r) of Z0.9997. The drug and
the two metabolites were stable in plasma samples. The validated method was successfully applied in a
bioequivalence and pharmacokinetic study with human volunteers under fasting condition.
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a)1. Introduction
Sibutramine hydrochloride monohydrate [(7)-dimethyl-1-[1-
(4-chlorophenyl)cyclobutyl]-N,N,3-trimethylbutan-1-amine
hydrochloride monohydrate] is currently used for the treat-
ment of obesity. The chemical formula of sibutramine is
C17H29Cl2NO and its molecular weight is 334.33. Sibutramine
acts by inhibiting the re-uptake of neurotransmitter serotonin,
norepinephrine and dopamine and enhancing satiety. Conse-
quently, it prevents compulsive eating and inhibits the sensa-
tion of hunger in obese patients [1,2]. Today obesity can be
considered as a chronic illness of epidemic proportion and its
Figure 1 Chemical structures of (a) sibutramine HCl, (b) N-des
methyl sibutramine HCl, (c) N-di des methyl sibutramine HCl,
(d) sibutramine d7 HCl, (e) N-des methyl sibutramine d7 HCl,
(f) N-di des methyl sibutramine d7 HCl.
V.S. Ponnuru et al.250incidents have increased exponentially [3]. For many patients,
dieting and physical exercise are not sufﬁcient to achieve and
maintain the desired weight loss. The use of anti-obesity drugs
such as sibutramine is needed.
Literature survey reveals that quantiﬁcation of sibutramine
in pharmaceutical, synthetic/dietary supplements and herbal
products was reported using LC–MS [4–7] and HPLC [8–11]
in biological matrices, e.g. rats [12–18]. Only a few methods
were reported for the quantiﬁcation of sibutramine and its two
metabolites in human plasma using LC–MS/MS [19–24].
Kang et al. [21] developed a method with the linearity range
of 0.1 – 0.8 ng/mL; they used imipramine as the internal
standard and a more complicated solid phase extraction
method to isolate sibutramine and its two metabolites. Ding
et al. [22] established a method with a linearity range of 0.05–
20.0 mg/L for sibutramine and N-des methyl sibutramine and
0.1–30.0 mg/L for N-di-des methyl sibutramine. They used
phenyl propyl amine hydrochloride as an internal standard,
liquid–liquid extraction for extraction of drug and IS and
compared test and reference formulations with 18 volunteers.
Chen et al. [23] reported a method with a linearity range of
0.328–32.8 ng/mL for sibutramine, N-Des methyl sibutramine
and N-di-des methyl sibutramine. They used liquid-liquid
extraction and propronolol as an internal standard and
compared test and reference formulations with 20 volunteers.
Bae et al. [24] developed a high-sensitivity method with a good
linearity range of 50–20000 pg/mL and a shorter runtime and
compared the drug and metabolites with chlorphenaramine as
an internal standard. However, we experienced many difﬁcul-
ties with the Bae’s method in terms of reproducibility and
stability in long run analysis.
It is important to develop a reliable bio-analytical method
with a properly deuterated derivative or other analog as the
internal standard to study the matrix effect and reproduci-
bility. It is not required to consider the runtime when
comparing the reproducibility and stability of analytical
batches. The goal of the present study was to develop a
reliable and accurate method for the quantiﬁcation of sibu-
tramine and its two metabolites with respective deuterated
internal standards. Moreover, the sample extraction method
should be simple and the analytical method should be highly
sensitive with good linearity and the use of a small amount of
plasma.2. Materials and methods
2.1. Chemicals and reagents
Sibutramine hydrochloride (SB) was purchased from Symed
labs. N-des-methyl sibutramine hydrochloride (DSB), N-di-
desmethyl sibutramine hydrochloride (DDSB), sibutramine d7
hydrochloride (SB d7), N-des-methyl sibutramine d7 hydro-
chloride (DSB d7), N-di-des methyl sibutramine d7 hydro-
chloride (DDSB d7) were obtained from Toronto Research
Chemicals, Canada (Fig. 1). Tertiary butyl methyl ether
(TBME), HPLC grade methanol and acetonitrile were pur-
chased from J.T. Baker, USA. Potassium dihydrogen phos-
phate (KH2PO4, reagent grade) and ammonium formate
(reagent grade) were purchased from Merck Limited, Worli,
Mumbai. Human plasma was obtained from Navajeevanblood bank, Hyderabad, India. Ultra pure water from
MilliQ-system (Millipore) was used throughout the study.2.2. Instrumentation
The Agilent 1200 Series HPLC system (Agilent Technologies,
Waldbronn, Germany) connected to the API 4000 triple
quadrupole instrument (ABI-SCIEX, Toronto, Canada) with
turbo electrospray interface in positive ionization mode was
used. Data processing was performed on Analyst 1.4.1 software
package (SCIEX).2.3. Detection
The mass transitions of m/z 280.3/124.9, 266.3/125.3, 252.2/
124.9, 287.3/125.2, 273.2/125.0, and 259.3/125.1 were used for
the quantiﬁcation of SB, DSB, DDSB, SB d7, DSB d7, and
DDSB d7, respectively (Table 1).2.4. Chromatographic conditions
Zorbax SB-C18 (4.6 mm 75 mm, 3.5 mm, 80 A˚) analytical
column was used and it was maintained at 40 1C. The mobile
phase consisted of 5 mM ammonium formate:acetonitrile
(10:90, v/v), which was run at a ﬂow-rate of 0.6 mL/min.
The analytes and internal standards were eluted at 9.2 min
(SB, SB d7), 8.2 min (DSB, DSB d7) and 6.2 min (DDSB,
DDSB d7) with a total runtime of 13 min for each injection.
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Standard stock solutions of SB (100.0 mg/mL), DSB (100.0 mg/
mL), DDSB (100.0 mg/mL) were prepared in methanol. From
each stock solution, 500.0 ng/mL, 25.0 ng/mL, 2.5 ng/mL inter-
mediate dilutions were prepared in plasma. Aliquots of 500.0 ng/
mL, 25.0 ng/mL and 2.5 ng/mL were used to spike blank human
plasma in order to obtain calibration standards at 10.0, 20.0,
200.0, 800.0, 1500.0, 3000.0, 4500.0, 6000.0, 7500.0 and
10,000.0 pg/mL. Four levels of quality control (QC) concentra-
tions at 10.0, 30.0, 3500.0 and 8000.0 pg/mL (lower limit of
quantiﬁcation (LLOQ), low quality control (LQC), medium
quality control (MQC) and high quality control (HQC)) were
prepared with different plasma lot. Spiked calibration standards
and quality control standards were stored at 30 1C until
analysis. Standard stock solutions of SB d7 (100.0 mg/mL),
DSB d7 (100.0 mg/mL) and DDSB d7 (100.0 mg/mL) were
prepared in methanol. SB d7, DSB d7 and DDSB d7 stock
solutions were further diluted to 30.0 ng/mL (spiked concentra-
tion of internal standard) with 50% methanol and stored in the
refrigerator at 2–8 1C until analysis.
2.6. Sample preparation
Liquid–liquid extraction was used to extract the drug and
internal standard. For this purpose, 100 mL of respective
plasma sample was placed in a polypropylene tube and mixed
with 50 mL of internal standard (30.0 ng/mL). This was
followed by addition of 100 mL of 10 mM KH2PO4 solution
and 2.5 mL of methyl tertiary butyl ether (MTBE) and
vortexed approximately for 5 min. The samples were then
centrifuged at 4000 rpm for 10 min at 20 1C. Subsequently, the
supernatant was transferred to respective polypropylene tubes
and evaporated under a stream of nitrogen gas at 40 1C. After
drying, samples were reconstituted with 200 mL of reconstitu-
tion solution (acetonitrile:5 mM ammonium formate (90:10, v/v))
and vortexed for 2 min. Finally, the samples were transferred to
autosampler vials and 20 mL was injected into the LC–MS/MS.
2.7. Selectivity and speciﬁcity
Selectivity was determined by analyzing the blank human
plasma samples from six different sources (donors) with an
additional hemolyzed group and lipidemic group to assessTable 1 Mass parameters of sibutramine (SB) and its two me
sibutramine (DDSB) and sibutramine d7 (SB d7), N-des methyl
(DDSB d7).
Compound name Transition of precursor molecular
Precursor molecular
ion (m/z)
Product
ion (m/z
Sibutramine 280.3 124.9
N-desmethyl sibutramine 266.3 125.3
N-di des methyl sibutramine 252.2 124.9
Sibutramine d7 287.3 125.2
N-des methyl sibutramine d7 273.2 125.0
N-di des methyl sibutramine d7 259.3 125.1
EP: entrance potential, DP: declustering potential, CE: collisional enerinterference at the retention times of analytes. The peak areas
of SB, DSB and DDSB in blank samples should not be more
than 20% of the mean peak area of LOQ of SB, DSB and
DDSB. Similarly, peak areas of SB d7, DSB d7 and DDSB d7
in a blank sample should not be more than 5% of the mean
peak area of LOQ of SB d7, DSB d7 and DDSB d7.
2.8. Precision and accuracy
Precision and accuracy were determined by replicate analysis of
quality control samples (n¼6) at low quality control (LQC),
medium quality control (MQC) and high quality control (HQC)
levels. The CV should be less than 15% and accuracy should be
within 15% except LLOQ where it should be within 20%.
2.9. Matrix effect
The matrix effect caused by plasma was evaluated by examin-
ing the ion suppression/enhancement in a signal when com-
paring the absolute response of QC samples after pretreatment
(liquid–liquid extraction with MTBE) with that of the recon-
stituted samples. Experiments in triplicate were performed at
MQC levels with 6 different plasma lots with the acceptable
precision (%CV) of r15%.
2.10. Recovery
The extraction efﬁciencies of SB, DSB, DDSB and SB d7, DSB
d7, and DDSB d7 were determined by analysis of 6 replicates at
each quality control concentration level for SB, DSB and
DDSB and at one concentration for the internal standard SB
d7, DSB d7 and DDSB d7. The percent recovery was evaluated
by comparing the peak areas of extracted standards to the peak
areas of non-extracted standards (blank plasma residue).
2.11. Limits of detection and quantiﬁcation (LOD and LOQ)
The limit of detection (LOD) is a parameter that deﬁnes the
lowest concentration in a sample that can be detected from
background noise but cannot be quantitated. LOD was
determined using the signal-to-noise ratio (s/n) of 3:1 by
comparing the results from samples of known concentrations
of analytes with blank samples. The limit of quantitation
(LOQ) is deﬁned as the lowest concentration of an analyte thattabolites N-des methyl sibutramine (DSB), N-di des methyl
sibutramine d7 (DSB d7), N-di des methyl sibutramine d7
ion to product ion Compound dependent parameters (V)
)
Run time
(min)
EP DP CE CXP
9.2 10 30 35 12
8.2 10 28 30 12
6.2 10 35 32 12
9.1 10 40 38 12
8.1 10 36 40 12
6.2 10 23 39 12
gy and CXP: collisional cell exit potential.
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The LOQ was found by analyzing a set of plasma standards
with known concentrations of SB, DSB and DDSB.
2.12. Stability
Stock solution stability was determined by comparing the area
response of analyte and internal standard in the stability
samples with the area response of samples prepared from fresh
stock solution. Stability studies in plasma were performed at
the LQC and HQC concentration levels using six replicates at
each level. Analyte was considered stable if the % change is
less than 15% as per US FDA guidelines [25]. The stability of
spiked human plasma samples stored at room temperature
(bench top stability) was evaluated for 72 h. The stability of
spiked human plasma samples stored at 30 1C in autosam-
pler (autosampler stability) was evaluated for 78 h. The
autosampler sample stability was evaluated by comparing
the extracted plasma samples that were injected immediately
(time 0 h), with the samples that were reinjected after storing
in the autosampler at 20 1C for 78 h. The reinjection reprodu-
cibility was evaluated by comparing the extracted plasma
samples that were injected immediately (time 0 h), with the
samples that were re-injected after storing in the autosampler at
20 1C for 27 h. The freeze–thaw stability study was conducted by
comparing the stability samples that had been frozen at 30 1C
and thawed three times, with freshly spiked quality control
samples. Six aliquots each of LQC and HQC concentration levels
were used for the freeze–thaw stability evaluation. For long term
stability evaluation, the concentrations obtained after 71 days
were compared with initial concentrations.
2.13. Analysis of human plasma samples
The validated method has been successfully used to analyze
SB, DSB and DDSB concentrations in the plasmas of 40
human volunteers under fasting conditions after oral admin-
istration of a single capsule containing 15 mg (1 15 mg) SB,
DSB and DDSB. The study was designed as a randomized,
two-period, two-sequence, two-treatment, single dose, and
open label bioequivalence study. The reference formulation
was used as MERIDIA Capsule (15 mg, Abbot, USA) and the
test formulation was used for APL Research Pvt. Ltd (15 mg,
Test capsule), India. The study was conducted according to
current GCP guidelines and after the volunteer signed written
consent. The study protocol was also approved by an
authorized ethics committee. There were a total of 28 blood
collection time points including the predose sample. The blood
samples were collected at time intervals of 0, 0.33, 0.5, 0.667,
0.833, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5, 6, 7, 8,
10, 12, 16, 24, 36, 48, 60, 72 and 96 h in separate vacutainers
containing K2EDTA as an anticoagulant. The plasma was
separated from the blood by centrifugation at 3500 rpm, 2–
8 1C for 10 min, and kept at 30 1C until sample analysis. Test
and reference were administered separately to the same human
volunteers under fasting conditions with proper washing
periods as per protocol approved by IEC.
2.14. Pharmacokinetics and statistical analysis
Post analysis was conducted and the pharmacokinetic para-
meters were obtained using Win-Nonlins software version9.2. Blood samples were collected for a period of 3–5 times
that of the terminal elimination half-life (t1/2). As per standard
guidelines AUC0–t, AUC0–N, Cmax, t1/2 and tmax were calcu-
lated for SB, DSB and DDSB in plasma samples. According
to regulatory guidelines AUC0–t, AUC0–N and Cmax values
should be within 80–125% for test and reference products
[26,27].3. Results and discussion
3.1. Method development and validation
The goal of this work was to develop and validate a simple,
rapid and sensitive method for the quantitative determination
of SB, DSB and DDSB in plasma samples. LC–MS/MS has
been used as one of the most powerful analytical tools in
clinical pharmacokinetics for its selectivity, sensitivity and
reproducibility. The MS optimization was performed by direct
infusion of SB, DSB, DDSB and SB d7, DSB d7, DDSB d7
solutions into the ESI source of the mass spectrometer. The
vital parameters like ionization with positive mode, tempera-
ture at 400 1C, ion spray voltage at 5500 V, gas parameters
such as nebulizer gas at 20 psi and heater gas at 40 psi were
obtained and compound parameters like declustering potential
(DP), entrance potential (EP), collision energy (CE) and
collision cell exit Potential(CXP) were individually optimized
(Table 1) to obtain the highest sensitivity and most efﬁcient
ionization to form the respective product ions from the
protonated SB, DSB, DDSB and SB d7, DSB d7, DDSB d7
molecules (Fig. 2). Chromatographic conditions, especially the
composition of the mobile phase and selection of suitable column,
were optimized through several trials to achieve the best resolu-
tion and highest signals of analytes and internal standards.
Different extraction methods like solid phase extraction, liquid–
liquid extraction and precipitation methods were optimized for
extraction of SB, DSB, DDSB and SB d7, DSB d7, DDSB d7
from the plasma samples. Good separation and elution were
achieved using 5 mM ammonium formate:acetonitrile (10:90, v/v)
as the mobile phase, at a ﬂow-rate of 0.6 mL/min with 20 mL
injection volume. Liquid–liquid extraction was chosen to recover
the drug and internal standard from the plasma. The retention
time was optimized at 9.2, 8.2, 6.2 min for SB, DSB, DDSB and
9.1, 8.1, 6.2 min for SB d7, DSB d7, DDSB d7, respectively
(Fig. 3).3.2. Linearity
Calibration curve was plotted as the peak area ratio (SB/SB
d7, DSB/DSB d7 and DDSB/DDSB d7) versus (SB, DSB,
DDSB) concentration. Calibration was found to be linear over
the concentration range of 10.0–10,000.0 pg/mL. The correla-
tion coefﬁcient (r2) was greater than 0.9997 for all curves
(Table 2).3.3. Selectivity
The selectivity of the method was assessed by comparing
chromatograms of blank plasma. No signiﬁcant endogenous
peaks were observed at respective retention time of SB, DSB,
Figure 2 (a) Parent ion mass spectra of sibutramine (SB), (b) product ion mass spectra of sibutramine, (c) parent ion mass spectra of N-
des methyl sibutramine (DSB), (d) product ion mass spectra of N-des methyl sibutramine, (e) parent ion mass spectra of N-di des methyl
sibutramine (DDSB), and (f) product ion mass spectra of N-di des methyl sibutramine.
Figure 3 Chromatogram of (a) sibutramine, (b) sibutramine d7, (c) N-des methyl sibutramine, (d) N-des methyl sibutramine d7, (e) N-di
des methyl sibutramine and (f) N-di des methyl sibutramine d7.
Quantiﬁcation of sibutramine in human plasma by LC–ESI-MS/MS 253DDSB and SB d7, DSB d7, DDSB d7. The results indicate
that the method was speciﬁc and selective (Fig. 4).
3.4. Precision and accuracy
Precision and accuracy of this method were evaluated by
calculating within-run and between-run variations at three
concentrations (30.0, 3500.0 and 8000.0 pg/mL) of QC samples
in six replicates. As shown in Table 3, within-run precision
and accuracy were in the range of 1.3–2.9% and 99.0–99.9%
for SB, 1.6–3.4% and 97.1–98.7% for DSB, 1.6–2.8 and 96.3–
98.7% for DDSB, respectively. Similarly, between-run preci-
sion and accuracy were in the range of 1.6–2.8% and 99.4–101.7% for SB, 1.2–3.2% and 99.3–99.8% for DSB, 2.1–3.4%
and 98.0–100.4% for DDSB, respectively. These results indicate
that the method showed adequate reliability and reproducibility
within the calibration curve range.3.5. Matrix effect
The ion suppression/enhancement in the signal at MQC level
was found to be CV 1.27 for SB, 1.20 for DSB and 1.30 for
DDSB. These results indicate that there is minimum effect on
ion suppression and ion enhancement at analyte and IS
retention time.
Table 2 Calibration curve details of sibutramine, N-des methyl sibutramine, N-di des methyl sibutramine.
Spiked plasma
concentration
(pg/mL)
Sibutramine N-des methyl sibutramine N-di des methyl sibutramine
Concentration measured
(mean7SD, pg/mL,
n¼5)
Precision
(CV, %,
n¼5)
Concentration measured
(mean7SD, pg/mL,
n¼5)
Precision
(CV, %,
n¼5)
Concentration measured
(mean7SD, pg/mL,
n¼5)
Precision
(CV, %,
n¼5)
10.0 9.870.0 0.4 9.970.0 0.2 9.970.1 1.5
20.0 20.470.3 1.7 19.870.3 1.4 20.470.4 2.2
200.0 200.175.2 2.6 198.676.2 3.1 198.776.2 3.1
800.0 798.5722.4 2.8 800.5719.2 2.4 782.5727.4 3.5
1500.0 1487.6728.3 1.9 1532.4721.5 1.4 1486.5741.6 2.8
3000.0 2964.2783.0 2.8 2856.2791.4 3.2 2964.87100.8 3.4
4500.0 4505.47108.1 2.4 4863.27121.6 2.5 4478.97107.5 2.4
6000.0 5976.57203.2 3.4 5986.67215.5 3.6 5863.47111.4 1.9
7500.0 7486.57187.2 2.5 7568.97136.2 1.8 7469.67283.8 3.8
10,000.0 9967.97123.8 1.2 9768.97146.2 1.4 9869.67213.8 2.2
SD: Standard Deviation.
Figure 4 Blank plasma chromatograms of sibutramine, sibutramine d7, N-des methyl sibutramine, N-des methyl sibutramine d7, N-di
des methyl sibutramine and N-di des methyl sibutramine d7.
Table 3 Precision and accuracy (analysis with spiked plasma samples at three different concentrations).
Compound
name
Spiked plasma
concentration
(pg/mL)
Within-run (n¼6) Between-run (n¼30)
Concentration measured
(pg/mL, mean7SD)
Precision
(CV, %)
Accuracy
(%)
Concentration measured
(pg/mL, mean7SD)
Precision
(CV, %)
Accuracy
(%)
Sibutramine 30.0 29.770.4 1.3 99.0 30.570.5 1.6 101.7
3500.0 3496.47101.4 2.9 99.9 3488.4776.7 2.2 99.7
8000.0 7958.57191.0 2.4 99.5 7952.87222.7 2.8 99.4
N-des methyl
sibutramine
30.0 29.270.5 1.6 97.3 29.870.4 1.2 99.3
3500.0 3398.57115.5 3.4 97.1 3476.4797.3 2.8 99.3
8000.0 7892.67221.0 2.8 98.7 7980.87255.4 3.2 99.8
N-di
desmethyl
sibutramine
30.0 28.970.5 1.6 96.3 29.470.7 2.4 98.0
3500.0 3426.7795.9 2.8 97.9 3512.47119.4 3.4 100.4
8000.0 7896.47189.5 2.4 98.7 7945.67166.9 2.1 99.3
V.S. Ponnuru et al.2543.6. Recovery
The extraction recoveries of SB, DSB and DDSB were
determined at three different concentrations 30.0, 3500.0,
8000.0 pg/mL and found to be 99.673.5%, 88.272.7% and97.6074.7% for SB, 95.579.7%, 92.6710.2% and 92.374.7%
for DSB, 99.272.4%, 94.271.7% and 94.576.1% for
DDSB, respectively. The overall average recoveries of SB,
DSB, DDSB and SB d7, DSB d7, DDSB d7 were found to
be 95.176.1%, 93.571.8%, 96.072.8% and 98.174.5%,
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Quantiﬁcation of sibutramine in human plasma by LC–ESI-MS/MS 25598.377.1%, 98.776.4%, respectively. Recoveries of the analyte
and IS were consistent, precise and reproducible.3.7. LOD and LOQ
The limit of detection was used to determine the instrument
detection levels for SB, DSB, DDSB at low concentrations.
5 mL of 0.5 pg/mL SB, DSB, DDSB solution was injected and
the determined LOD was 4.5 fg for SB, 3.5 fg for DSB and
4.0 fg for DDSB with S/N values Z3–5. The signal-to-noise
(S/N) values found for six injections of SB, DSB, and DDSB
at LOQ concentration were 31.95, 40.23 and 44.12,
respectively.3.8. Stability
Stock solution stability study was performed to check stability
of SB, DSB, DDSB and SB d7, DSB d7, DDSB d7 stock
solutions at 2–8 1C in a refrigerator. The freshly prepared
stock solutions were compared with stock solutions prepared
26 days ago. The changes of SB, DSB, DDSB and SBd7,
DSBd7, DDSBd7 were 0.02% and 0.03% respectively,
indicating that the stock solutions were stable for at least 26
days. Room temperature stability, autosampler stability,
freeze–thaw stability and long term stability for SB, DSB
and DDSB were investigated at LQC and HQC levels. The
results revealed that SB, DSB and DDSB were stable in
plasma for at least 72 h at room temperature, and 78 h in an
autosampler. Freezing and thawing (three cycles) of plasma
samples spiked with SB, DSB and DDSB at LQC and HQC
levels did not affect their stability. The long-term stability
results also indicated that SB, DSB and DDSB were stable in
plasma up to 71 days at 30 1C. The results obtained from all
these stability studies are tabulated in Table 4. Precision (CV)
is less than 5% for room temperature, long-term, Freeze–
thaw, and autosampler stabilities.Figure 5 Mean plasma concentration of sibutramine, N-des
methyl sibutramine, and N-di des methyl sibutramine.
Table 5 Mean pharmacokinetic parameters of sibutramine, N-des methyl sibutramine, and N-di des methyl sibutramine in 40
healthy human volunteers after oral administration of 15 mg test and reference products (mean7SD).
Pharmacokinetic
parameter
Sibutramine N-des methyl sibutramine N-di des methyl sibutramine
Test Reference Test Reference Test Reference
Cmax (pg/mL) 4065.471481.2 4368.571654.4 4027.871420.6 4067.771451.9 6724.472341.2 6579.872294.6
AUC0–t (pg h/mL) 18,566.27729.3 22,168.17862.1 85,931.972898.0 93,405.973322.5 174,389.876977.7 182,500.97698.5
AUC0–N (pg h/mL) 19,560.27782.1 23,296.97934.5 92,464.173121.0 100,736.173402.4 184,885.777432.4 194,500.978326.3
tmax (h) 1.5 1.5 6.0 6.0 6.0 6.0
t1/2 3.7 3.6 27.2 25.5 23.9 23.6
AUC0–N: Area under the curve extrapolated to inﬁnity.
AUC0–t: Area under the curve up to the last sampling time.
Cmax: The maximum plasma concentration.
tmax: The time to reach peak concentration.
Table 6 Test vs. reference pharmacokinetic parameters of
sibutramine, N-des methyl sibutramine and N-di des
methyl sibutramine after administration of 15 mg of test
and reference products in 40 healthy human volunteers.
Pharmacokinetic
parameters
Test/reference
Sibutramine N-des
methyl
sibutramine
N-di des
methyl
sibutramine
Cmax 93.1 99.0 102.2
AUC0–t 92.1 91.9 95.6
AUC0–N 83.9 91.8 95.1
V.S. Ponnuru et al.2563.9. Application to biological samples
The validated method was used successfully to quantify
plasma SB, DSB and DDSB concentrations of 40 healthy
volunteers who received oral administration of 15 mg dose
(one 15 mg capsule) under fasting conditions. Mean plasma
concentration versus time proﬁles are shown in Fig. 5. All the
plasma concentrations of SB, DSB and DDSB were within the
standard calibration region and remained above LOQ
(10.0 pg/mL) for the entire sampling period. The detailed
pharmacokinetic parameters are shown in Tables 5 and 6. In
addition, the mean ratio of AUC0–t/AUC0–N was higher than
90% following the FDA Bioequivalence Guidelines [26,27].
The ratio of test/reference (T/R) for overall analysis was in the
range of 80–125%.4. Conclusion
The developed method is highly speciﬁc due to the inherent
selectivity of tandem mass spectrometry and has signiﬁcant
advantages over previously reported methods in terms of
selectivity, sensitivity, linearity and reproducibility. Quantiﬁ-
cation of sibutramine and its two metabolites was compared
with respective isotope labeled internal standards. Extraction
of analyte and IS was achieved using liquid-liquid extraction.
Mobile phase, column, ﬂow rate, injection volume, plasma
usage volume for analysis were improved. The bioequivalencestudy also demonstrated that the two sibutramine formula-
tions (reference and test) are bioequivalent.Acknowledgments
Authors wish to thank the support received from IICT (Indian
Institute of Chemical Technology), Hyderabad, India for provid-
ing literature survey, APL Research Pvt. Ltd., Hyderabad, India
to carry out this Research work.References
[1] E. Kristina, R. Stephan, B. Britta, et al., Sibutramine treatment in
obesity: initial eating behaviour in relation to weight loss results
and changes in mood, Pharmacol. Res. 51 (2005) 159–163.
[2] K. Heusser, J. Tank, A. Diedrich, et al., Inﬂuence of sibutramine
treatment on sympathetic vasomotor tone in obese subjects, Clin.
Pharmacol. Ther. 79 (2006) 500–508.
[3] D. Sucar, E.B. Sougey, J.B. Neto, Psychotic episode induced by
potential drug interaction of sibutramine and ﬁnasteride, Rev.
Bras. Psiquiatr. 24 (2002) 30–33.
[4] Y. Chen, L. Zhao, F. Lu, et al., Determination of synthetic drugs
used to adulterate botanical dietary supplements using QTRAP
LC–MS/MS, Food Addit. Contam. Part A Chem. Anal. Control
Expo. Risk Assess. 26 (5) (2009) 595–603.
[5] P. Zou, S.S. Oh, K.H. Kiang, et al., Detection of sibutramine, its
two metabolites and one analogue in a herbal product for weight
loss by liquid chromatography triple quadrupole mass spectro-
metry and time-of-ﬂight mass spectrometry, Rapid Commun.
Mass Spectrom. 21 (4) (2007) 614–618.
[6] J. Chen, W. Lu, Q. Zhang, et al., Determination of the active
metabolite of sibutramine by liquid chromatography–electrospray
ionization tandem mass spectrometry, J. Chromatogr. B Anal.
Technol. Biomed. Life Sci. 785 (2) (2003) 197–203.
[7] S.H. Kim, J. Lee, T. Yoon, et al., Simultaneous determination of
anti-diabetes/anti-obesity drugs by LC/PDA, and targeted ana-
lysis of sibutramine analog in dietary supplements by LC/MS/
MS, Biomed. Chromatogr. 12 (2009) 1259–1265.
[8] I.C. Diefenbach, M. Friedrich, M.R. Dos, et al., Development
and validation of a column high-performance liquid chromato-
graphic method for determination of sibutramine in capsules,
J. AOAC Int. 92 (1) (2009) 148–151.
[9] Z. Huang, S. Xiao, D. Luo, et al., Simultaneous determination of
sibutramine and N-Di-desmethylsibutramine in dietary supple-
ments for weight control by HPLC–ESI-MS, J. Chromatogr. Sci.
46 (8) (2008) 707–711.
Quantiﬁcation of sibutramine in human plasma by LC–ESI-MS/MS 257[10] A.K. Singh, L.G. Pedro, F.P. Gomes, et al., Development and
validation of sensitive methods for determination of sibutramine
hydrochloride monohydrate and direct enantiomeric separation
on a protein-based chiral stationary phase, J. AOAC Int. 91 (3)
(2008) 572–579.
[11] J.G. Chandorkar, V.B. Kotwal, N.S. Dhande, et al., Develop-
ment and validation of high performance liquid chromatography
method for analysis of sibutramine hydrochloride and its impur-
ity, Pak. J. Pharm. Sci. 21 (2) (2008) 121–124.
[12] K.S. Hakala, M. Link, B. Szotakova, et al., Characterization of
metabolites of sibutramine in primary cultures of rat hepatocytes
by liquid chromatography–ion trap mass spectrometry, Anal.
Bioanal. Chem. 393 (4) (2009) 1327–1336.
[13] S.Y. Um, K.B. Kim, S.H. Kim, et al., Determination of the active
metabolites of sibutramine in rat serum using column-switching
HPLC, J. Sep. Sci. 31 (15) (2008) 2820–2826.
[14] A. Balcioglu, R.J. Wurtman, Sibutramine, a serotonin uptake
inhibitor, increases dopamine concentrations in rat striatal and
hypothalamic extracellular ﬂuid, Neuropharmacology 39 (12)
(2000) 2352–2359.
[15] D.J. Heal, A.T. Frankland, W.R. Buckett, et al., A new and
highly sensitive method for measuring 3-methoxytyramine using
HPLC with electrochemical detection. Studies with drugs which
alter dopamine metabolism in the brain, Neuropharmacology 29
(12) (1990) 1141–1150.
[16] D.J. Heal, M.R. Prow, W.R. Buckett, et al., Measurement of 3-
methoxy-4-hydroxyphenylglycol (MHPG) in mouse brain by
HPLC with electrochemical detection, as an index of noradrena-
line utilisation and presynaptic alpha 2-adrenoceptor function,
Br. J. Pharmacol. 96 (3) (1989) 547–556.
[17] A.C. Franco Spinola, S. Almeida, A. Filipe, et al., Comparative
bioavailability of two formulations of sibutramine, Int. J. Clin.
Pharmacol. Ther. 47 (10) (2009) 627–637.
[18] W. Kang, K. Bae, K. Noh, et al., Enantioselective determination
of sibutramine and its active metabolites in human plasma,
J. Pharm. Biomed. Anal. 51 (1) (2010) 264–267.
[19] D.S. Jain, G. Subbaiah, M. Sanyal, et al., Liquid chromatogra-
phy/electrospray ionization tandem mass spectrometry validatedmethod for the simultaneous quantiﬁcation of sibutramine and its
primary and secondary amine metabolites in human plasma and
its application to a bioequivalence study, Rapid Commun. Mass
Spectrom. 20 (23) (2006) 3509–3521.
[20] Z. Abolfathi, J. Couture, F. Vallee, et al., A pilot study to
evaluate the pharmacokinetics of sibutramine in healthy subjects
under fasting and fed conditions, J. Pharm. Pharm. Sci. 7 (3)
(2004) 345–349.
[21] W. Kang, K. Bae, K. Noh, et al., Enantioselective determination
of sibutramine and its active metabolites in human plasma,
J. Pharm. Biomed. Anal. 51 (1) (2010) 264–267.
[22] L. Ding, X. Hao, X. Huang, et al., Simultaneous determination of
sibutramine and its N-desmethyl metabolites in human plasma by
liquid chromatography–electrospray ionization-mass spectrome-
try: method and clinical applications, Anal. Chim. Acta 492
(2003) 241–248.
[23] J. Chen, W. Lu, Q. Zhang, et al., Determination of the active
metabolite of sibutramine by liquid chromatography–electrospray
ionization tandem mass spectrometry, J. Chromatogr. B 785
(2003) 197–203.
[24] J.W. Bae, C.I. Choi, C.G. Jang, et al., Simultaneous determina-
tion of sibutramine and its active metabolites in human plasma by
LC–MS/MS and its application to a pharmacokinetic study,
Biomed. Chromatogr. (2011), doi:10.1002/bmc.1587.
[25] Guidance for Industry: Bioanalytical Method Validation, U.S.
Department of Health and Human Services, Food and Drug
Administration, Center for Drug Evaluation and Research (CDER),
Center for Biologics Evaluation and Research (CBER), May 2001.
[26] Guidance for Industry: Food-effect Bioavailability and Fed
Bioequivalence Studies, U.S. Department of Health and Human
Services, Food and Drug Administration, Centre for Drug
Evaluation and Research (CDER), December 2002.
[27] Guidance for Industry: Bioavailability and Fed Bioequivalence
Studies for Orally Administered Drug Products—General Con-
siderations, U.S. Department of Health and Human Services,
Food and Drug Administration, Centre for Drug Evaluation and
Research (CDER), March 2003.
